Malignant Gastric Neoplasm — Trials

Malignant Gastric Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 650
Recruiting: 353
Ph III recruiting: 49
Growth YoY: +13.6%
Industry share: 26%
Top sponsor: Fudan University
Termination share: 26.1%
Trials / 1,000 deaths: 59.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (232)

clinicaltrialsPublishedShowing 2,551–2,600 of 2,844 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00553683	Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer	unknown	Phase 1 / Phase 2	50	Rutgers, The State University of New JerseyOTHER	1	Jan 14, 2014	clinicaltrials
NCT01070290	A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen	withdrawn	Phase 2	0	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)